SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility driven by renewed tariff threats against European allies, tied to geopolitical tensions over Greenland, sparking widespread market apprehension. The community is sharply divided between those anticipating a major pullback and those expecting a rapid "buy the dip" recovery, citing the market's historical resilience to such headlines. This situation unfolds as participants also eye a potential Supreme Court ruling on tariffs, which could further influence market direction.

KiboShib (KIBSHI) is the first AI-generated meme coin. On December 8th 2022, AI was tasked with creating a meme coin. It all started as a joke, but the idea which was proposed by the AI is so powerful that nobody could resist! The AI even suggested a logo design which later has been fed to the AI image generator. The age of AI is upon us, and KiboShib stands for exploring the capabilities of AI with a hopeful outlook.

KiboShib

KIBSHI CRYPTO is trending as the community rallies around its unique narrative as the first AI-generated meme coin, created by ChatGPT in 2022. This narrative, combined with growing AI hype, fuels discussions about its potential for substantial gains, with many comparing it to the early explosive runs of $DOGE and $SHIB. Investors are actively discussing its low market capitalization and positioning for what they anticipate could be a significant opportunity in the upcoming altcoin cycle.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF ($TLT) is heavily trending due to a confluence of political and economic events. Market participants are actively discussing former President Trump's new tariff threats, his directive for $200 billion in mortgage bond purchases, and the looming Supreme Court decision on existing tariffs, alongside a DOJ probe into Fed Chair Powell. These developments have sparked intense debate among investors over whether yields will fall, boosting TLT, or if inflation and geopolitical risks will keep rates elevated.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is trending as it expands its pipeline with recent acquisitions of VLX-1005 and Frunexian, alongside progress in manufacturing its lead candidate, tecarfarin, which holds FDA Fast Track status. The community is sharply divided, with bulls pointing to clinical potential and analyst price targets, while skeptics voice concerns over recurrent stock dilution, significant cash burn, and perceived bot activity fueling conversation on social media.

Oasis is a layer-one blockchain built to support confidential applications at scale. It’s home to Sapphire, the world’s first private EVM network, Oasis Privacy Layer, a cross-chain privacy solution for any EVM dApp, and Runtime Offchain Logic, a framework that brings trustworthy off-chain computing, onchain. Powered by its ROSE token, Oasis leverages a unique layered architecture and native rollup support, making it ideal for use cases in AI, DeFi, DAOs, gaming, and more.

Oasis Network

Oasis Network (ROSE) is trending as the community eagerly discusses its strong pivot into the AI narrative, with an anticipated rebrand to "Rose AI." Its foundational role in privacy-preserving AI, confidential computing, and Web3 developments is generating significant enthusiasm, positioning it as an undervalued asset with substantial growth potential.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amid heightened geopolitical tensions sparked by recent tariff threats between the U.S. and European nations concerning Greenland, triggering a broad risk-off sentiment and significant liquidations in the crypto market. The community is actively debating whether this presents a buying opportunity or signals further declines, with many questioning Bitcoin's role as a safe haven asset amidst the escalating global uncertainty.

Sleep Number Corp. engages in the design, manufacture, marketing, and distribution of beds, proprietary beds, and other sleep-related accessory products. It offers beds under the brand name Sleep Number. The company was founded by Robert Walker and JoAnn Walker in 1987 and is headquartered in Minneapolis, MN.

Sleep Number Corp

Sleep Number is trending after disappointing quarterly results and a lowered outlook, sparking a significant stock decline. The community is sharply divided between those fearing a 'death spiral' amid industry headwinds and high debt, and others who see an overreaction, pointing to high short interest and potential for a squeeze.

Wishing Well

WISH CRYPTO is actively trending as its community rallies around a HODL challenge, aiming for a significant market cap milestone to unlock rewards. The project differentiates itself with ongoing token burns tied to US inflation rates, frequent airdrops, and a strong community focus, driving discussions around its long-term potential as a deflationary memecoin on Solana.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing a surge in attention following significant global approvals for its Anktiva cancer therapy, notably for lung and bladder cancer, challenging established treatment paradigms. This development, combined with high short interest and the company's leadership actively promoting the science, has fueled community discussions around a potential short squeeze and a transformative shift in the biotech sector. Investors are keenly focused on the accelerated revenue prospects and broader market adoption of these innovative treatments.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital Corp. is experiencing intense negative sentiment following a notable NAV decline and the recent discontinuation of its dividend reinvestment plan discount, leading many investors to express frustration and liquidate holdings. Despite this, a segment of the community remains committed, emphasizing the stock's substantial dividend yield and significant discount to NAV as a long-term opportunity. The ongoing debate over the sustainability of its distributions and the broader market's cautious outlook on CLOs continues to fuel highly polarized discussions ahead of its imminent earnings report.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Donoghue Forlines LLC Takes $2.11 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Donoghue Forlines LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Growth in Short Interest

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest...

Wolverine Asset Management LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Wolverine Asset Management LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and...

Campbell & CO Investment Adviser LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Campbell & CO Investment Adviser LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the third quarter, according to the company in its most recent...

A Look Into Alnylam Pharmaceuticals Inc's Price Over Earnings

EVP Of Alnylam Pharmaceuticals Sold $547K In Stock

Insider Selling: Jeffrey V Poulton Unloads $1.01M Of Alnylam Pharmaceuticals Stock

Alnylam Pharmaceuticals Chief Executive Officer Sold $3.48M In Company Stock

Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $848,055.70 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The stock...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-seven ratings firms that are currently covering the firm...

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

ALNY
Alnylam Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALNY News

ALNYAlnylam Pharmaceuticals Inc